

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SUPPLEMENTAL ANNOUNCEMENT  
MAJOR TRANSACTION IN RELATION TO ACQUISITION OF 100%  
OF THE ISSUED SHARES IN THE TARGET COMPANIES  
INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER  
SPECIFIC MANDATE**

Reference is made to the announcement of China NT Pharma Group Company Limited (the “**Company**”) dated 28 April 2025 and the clarification announcement dated 29 April 2025 (the “**Announcements**”) in relation to acquisition of 100% of the issued shares in the Target Companies involving the issue of Consideration Shares under Specific Mandate. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

The Board wishes to announce that on 18 December 2025, the Purchaser and the Sellers entered into a supplemental agreement (the “**Supplemental Agreement**”) to amend the payment terms of the Consideration in the Sale and Purchase Agreement. The principal amendments to the Sale and Purchase Agreement contained in the Supplemental Agreement are set out below:

- (i) the manner in which the consideration of RMB116,219,960 (equivalent to approximately HKD123,638,256 at exchange rate of HKD1.00 to RMB0.94) (the “**Consideration**”) shall be paid by the Purchaser to the Vendor has been amended as follows:
  - (a) The total consideration for the sale of the Sale Shares is RMB116,219,960 (equivalent to approximately HKD123,638,256 at exchange rate of HKD1.00 to RMB0.94), which shall be satisfied by the Purchaser allotting and issuing to each of the Sellers, credited as fully paid, Consideration Shares set out opposite their respective names in Schedule I.

- (b) The Purchaser shall procure the Company to allot 100% of the Consideration Shares to each of the Sellers on a pro rata basis within 30 days after successful completion of registration and having obtained medical device registration certificate of the Portable Digital X-Ray Diagnostic Robot System (便攜式數位 X 光診斷機器人系統) at Zhejiang Province Food and Drugs Administration (浙江省食品藥物管理局) and after Closing.
- (ii) The definition of Long Stop Date as defined in Sale and Purchase Agreement shall be amended to mean “28 April 2026, or such other date as the parties to this Agreement may agree in writing”.

Save for the amendments disclosed above, there is no material change to the other terms of the Agreement and they shall remain effective.

By order of the Board of Directors  
**China NT Pharma Group Company Limited**  
**Mr. Ng Tit**  
*Chairman*

Hong Kong, 18 December 2025

*As at the date of this announcement, the executive Directors are Mr. Ng Tit and Ms. Ng Anna Ching Mei; the non-executive Director is Dr. Qian Wei and Ms. Chin Yu; and the independent non-executive Directors are Mr. Yu Tze Shan Hailson, Mr. Ng Ming Kwan and Dr. Zhao Yubiao.*